Anindya Das¹*, Arpita Neogi², Parthajit Banerjee³, Subhrajit Sengupta⁴ and Meghna Kundu⁴

¹Assistant Professor, Department of Microbiology, KPC Medical College and Hospital, West Bengal University of Health Science, Kolkata, India

*Corresponding Author: Anindya Das, Assistant Professor, Department of Microbiology, KPC Medical College and Hospital, West Bengal University of Health Science, Kolkata, India.

Received: July 04, 2022; Published: July 19, 2022

Abstract

Coronavirus disease 2019 (COVID19) is predominantly a respiratory tract infection sometimes presenting as a viral fever and sometimes having more severe presentation involving other systems also. This is a condition caused by a novel coronavirus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2; called 2019-nCoV). It was first identified when an outbreak of respiratory illness transgressed throughout the Wuhan City, Hubei Province, China. Similar to many other infectious diseases, not only the humoral immunity but also the T-cell mediated immunity in the form of acquired immunity, is important in the elimination of pathogens, including SARS-CoV-2. Viral surface glycoproteins like the spike glycoprotein and the nucleocapsid protein plays important role in the generation of humoral immune responses to SARS-CoV-2, as they stimulate the production of antibodies. The current study was conducted to evaluate the immune response of the people by the development of virus specific IgG antibodies. 78 subjects were enrolled in the study and estimation of IgG antibody of COVID-19 among fully vaccinated, partially vaccinated, triple vaccinated and non-vaccinated individuals was done by ELISA. The inclusion criteria was the patients seeking admission in the hospital, undergoing RT-PCR test and further work up; and the exclusion criteria was the patients undergoing RT-PCR test for travel or other purposes, not seeking hospital admission. Our findings were that after COVID-19 vaccination sero-positivity to nucleocapsid and spike protein antigens developed in 92% of the individuals participating in the study. It was also observed that 26% vaccinated people developed mildly positive IgG antibody titer (1.1 - 3.0 U/ml); 56.5% vaccinated people developed moderately positive (3.0 - 10.0 U/ml) and 17% vaccinated people developed strongly positive (> 10.0 U/ml) COVID 19 IgG antibody titer. The vaccines are an efficacious tool to combat the deadly disease where they have reduced the chance of hospitalization and complications caused by the disease.

Keywords: SARS-CoV-2; IgG antibody; Spike Glycoprotein; Nucleocapsid Protein; ELISA

References

1. Abdulrahman A., et al. “Association between RT-PCR Ct values and COVID-19 new daily cases: a multicenter cross-sectional Study”. medRxiv (2020).
2. Yadav PD., et al. “Isolation and characterization of VUI-202012/01, a SARS-CoV-2 variant in travellers from the United Kingdom to India”. Journal of Travel Medicine 88 (2021): 65.
3. Loconsole D., et al. “Genome sequence of aSARS-CoV-2 VUI 202012/01 strain identified from a patient returning from London, England, to the Apulia Region of Italy”. Microbiology Resource Announcements 4 (2021): e01487-e1520.
4. van Oosterhout C., et al. “COVID-19 evolution during the pandemic— implications of new SARS-CoV-2 variants on disease control and public health policies”. Virulence1 (2021): 507-508.
5. Tang JW., et al. “Introduction of the South African SARS- CoV-2 variant 501Y.V2 into the UK”. Journal of Infection (2021): S0163-4453 (21)00030-X.
6. Baglivo M., et al. “Natural small molecules as inhibitors of coronavirus lipid- dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?” Acta Biomedicine1 (2020): 161-164.
7. Wang Q., et al. “A unique protease cleavage site predicted in the spike protein of the novel pneumonia coronavirus (2019-nCoV) potentially related to viral transmissibility”. Virologica Sinica 5 (2020): 1-3.
8. Coutard B., et al. “The spike glycoprotein of the new coronavirus 2019- nCoV contains a furin like cleavage site absent in CoV of the same clade”. Antiviral Research 176 (2020): 5.
9. Yu H., et al. “Genomic analysis of a 2019-nCoV strain in the first COVID-19 patient found in Hangzhou, Zhejiang, China”. Zhonghua yu Fang yi xue za zhi 54 (2020): E026.
10. Zhang T., et al. “Probable pangolin origin of 2019-nCoVassociated with outbreak of COVID-19”. Current Biology 20 (2020): 299.
11. Vankadari N and Wilce JA. “Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26”. Emerging Microbes and Infections 1 (2020): 601-604.
12. Ortega N., et al. “Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses”. Nature Communication 12 (2021): 4740.
13. Dugas M., et al. “Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)”. The International Journal of Infectious Diseases 105 (2020): 304-306.
14. Leisman DE., et al. “Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes”. Lancet Respiratory Medicine 28 (2020): 1233-1244.
15. Pyrc K., et al. “Mosaic structure of human coronavirus NL63, one thousand years of evolution”. Journal of Molecular Biology 364 (2006): 964-973.
16. Sagar M., et al. “Recent endemic coronavirus infection is associated with less-severe COVID-19”. World Health Organization. 2020. Clinical management of COVID-19: interim guidance, 27 May (2020).
17. Sokal A., et al. “Maturation and persistence of the anti-SARS-CoV-2 memory B cell response”. Cell 184 (2021): 1201-1213.
18. Awadhesh Singh., et al. “Is ethnicity linked to incidence or outcomes of covid-19?” BMJ 369 (2020): m1548.

Citation

Citation: Anindya Das., et al. “Estimation of COVID-19 Antibody (IgG) Titer Among Fully Vaccinated, Partially Vaccinated and Non-vaccinated Individuals in a Tertiary Care Hospital in Eastern India". Acta Scientific Microbiology 5.8 (2022): 84-89.

Copyright

Copyright: © 2022 Anindya Das., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.